The 5-allyloxy-2-(pyrrolidine-1-yl) quinoline (APQ) is another newly discovered SETDB1 inhibitor that reduces H3K9me3 levels and improves motor and neuropathological symptoms in an HD model [148]. This evidence concerns the gene SETDB1 and Huntington disease.